Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sagimet Biosciences Inc. (NASDAQ: SGMT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sagimet is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, and its filings offer detailed insight into this development strategy, capital structure, and risk profile.
Through Forms 8-K, Sagimet reports material events such as clinical trial updates, license agreements, accounting firm changes, at-the-market equity sales arrangements, and quarterly financial results. For example, recent 8-K filings describe positive Phase 1 pharmacokinetic data for a denifanstat and resmetirom combination, a global license agreement with TAPI for innovative forms of resmetirom active pharmaceutical ingredient to support a fixed-dose combination program, and financial results for recent quarters. Other 8-Ks outline changes in the company’s independent registered public accounting firm and the establishment of an at-the-market offering program for its Series A common stock.
Investors and analysts can use this page to locate Sagimet’s periodic and current reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on clinical development progress for denifanstat and TVB-3567, funding arrangements, and risk factors related to MASH and acne programs. Forms 4 and other ownership-related filings, when present, can be used to monitor insider transactions in SGMT shares.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the significance of new 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new Sagimet filings appear promptly, while AI-generated highlights can clarify complex topics such as licensing terms, at-the-market sales agreements, and clinical trial disclosures. This makes the SGMT filings page a practical starting point for reviewing Sagimet’s regulatory history and ongoing obligations.
Sagimet Biosciences Inc. entered into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries. TAPI granted Sagimet a global, exclusive license to certain intellectual property covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient for Sagimet’s technical evaluation and manufacture.
If Sagimet elects to proceed after an evaluation period, the license also covers further development of a fixed-dose combination product containing denifanstat and resmetirom. Sagimet previously made a non-refundable up-front payment of $2.5 million to TAPI upon execution of a term sheet, and TAPI may be eligible for low single-digit royalties plus up to $5.5 million in additional manufacturing-related milestone payments. The agreement runs until specified TAPI know-how is no longer confidential or the last TAPI patent expires, unless terminated earlier under its terms.
Sagimet Biosciences Inc. (SGMT) reported an insider transaction by a director and Executive Chairman. On 11/20/2025, the reporting person sold 37,688 shares of Series A common stock in an open-market sale coded as "S." The weighted average sale price was $7.6942 per share, with individual trades executed between $7.27 and $8.15.
After this transaction, the insider beneficially owned 81,005 shares of Sagimet Biosciences common stock in direct ownership. The sale was carried out under a Rule 10b5-1 trading plan adopted on August 21, 2025, which is a pre-arranged plan designed to allow insiders to sell shares according to predetermined instructions.
Sagimet Biosciences (SGMT) furnished an update via Form 8-K. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and provided an updated investor presentation. Both materials are included as Exhibits 99.1 and 99.2 and are incorporated by reference.
The company noted that the press release and investor presentation are being furnished, not filed, under the Exchange Act. Representatives may use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) reported Q3 2025 results showing a net loss of $12.9 million as it advances its fatty acid synthase inhibitor programs. Operating expenses were $14.3 million, with research and development of $9.7 million, down 23% year over year on lower Phase 3 denifanstat clinical costs, partly offset by a $2.5 million up-front CMO license fee and new early‑stage studies. General and administrative expenses were $4.6 million.
Liquidity remained solid with cash, cash equivalents and marketable securities of $125.5 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company established a $75.0 million at‑the‑market program in August 2025 with no sales in the quarter. Accumulated deficit was $336.8 million.
Program updates: denifanstat met primary and multiple secondary endpoints in Phase 2b MASH and a Phase 1 PK trial combining denifanstat with resmetirom began in September 2025. In acne, Sagimet’s partner reported Phase 3 success in China and plans an NDA submission. Sagimet also began a Phase 1 trial of TVB‑3567 for acne in June 2025.
Sagimet Biosciences (SGMT)
The RSUs vest in four equal annual installments following November 4, 2025. The option vests over 48 equal monthly installments following November 4, 2025 and has an expiration date of 11/03/2035. After these grants, 193,581 Series A Common shares were beneficially owned directly, and 13,367 options were held.
Sagimet Biosciences (SGMT) furnished an updated investor presentation as Exhibit 99.1 to a Form 8-K. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished and are not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth in a future filing.
Representatives may use the updated presentation in meetings with investors from time to time. The filing is an informational Reg FD update and does not announce a transaction or financial results.
Sagimet Biosciences Inc. reported that its Board of Directors, following a recommendation from the Audit Committee, approved a change in independent auditors. Effective August 18, 2025, KPMG LLP was appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods, and Deloitte & Touche LLP was dismissed from this role.
The company states that Deloitte’s audit reports on the financial statements for the years ended December 31, 2024 and 2023 contained no adverse opinions, disclaimers of opinion, or qualifications, and that there were no disagreements with Deloitte on accounting principles, financial statement disclosure, or audit procedures during those periods and through August 18, 2025. Sagimet also notes that during the same periods it did not consult KPMG on specific accounting transactions or anticipated audit opinions before this appointment.
Sagimet Biosciences Inc. (Series A Common Stock, CUSIP 786700104) is the subject of an amended Schedule 13G filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0 shares and 0% of the Series A common stock and reports no sole or shared voting or dispositive power. The filing includes the issuer address and identifies the filers and their Delaware organization or U.S. citizenship where applicable. The submission contains a certification that the shares were not acquired to influence control of the issuer.
Sagimet Biosciences, Inc. reported the entry into a material definitive agreement on
Sagimet Biosciences Inc. filed a prospectus supplement to offer up to $75.0 million of Series A common stock through an "at-the-market" sales agreement with Leerink Partners. The company’s Series A common stock trades on Nasdaq under the symbol SGMT and the last reported sale price referenced was $9.58 per share on August 13, 2025. Net proceeds are intended to advance development of denifanstat and other FASN inhibitors, for R&D, working capital and general corporate purposes.
The supplement highlights clinical progress: denifanstat met both primary and multiple secondary endpoints in a Phase 2b FASCINATE-2 MASH trial (statistically significant histologic and MRI-PDFF results) and received FDA Breakthrough Therapy designation for non-cirrhotic MASH F2-F3. Ascletis reported positive Phase 3 acne results for denifanstat in China. Sagimet is exploring Phase 3 funding and will initiate a Phase 1 PK study of denifanstat plus resmetirom in H2 2025, and started a Phase 1 trial of second candidate TVB-3567 in June 2025.